EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

Taha Koray Sahin iD, Fatih Kemik iD, Harun Muglu, Bedriye Acikgöz Yildiz, Sedat Biter, Salih Tunbekici, Ahmet Oruc, Ali Kaan Guren, Kerim Kaban, Halil Goksel Guzel, Cihan Erol, Musa Baris Aykan iD und 41 weitere

Therapeutic Advances in Medical Oncology · 2026-03 · 18

DOI: 10.1177/17588359261430583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 13.03.2026. Verfasst von Taha Koray Sahin und 52 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hacettepe University Faculty of Medicine, Sihhiye, Ankara 06100, Turkey. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trastuzumab deruxtecan (T-DXd) has transformed the treatment landscape of human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC), with significant improvements in survival reported in clinical trials. However, limited data exist regarding its performance in real-world settings, particularly in lower-middle-income countries (LMICs).

Objectives

To evaluate the real-world effectiveness and safety of T-DXd in patients with HER2+ mBC in Türkiye.

Design

A multicenter retrospective cohort study.

Methods

This multicenter, retrospective cohort study, conducted by the Turkish Oncology Group, evaluated the real-world outcomes and tolerability of T-DXd in patients with HER2+ mBC across 27 oncology centers in Türkiye. The primary endpoints were real-world progression-free survival (rwPFS) and overall survival (rwOS). Secondary endpoints included response rate, safety (with adverse events (AEs) graded according to CTCAE v5.0), and evaluation of the first post-T-DXd treatments.

Results

A total of 269 patients were included. The median age was 49 years (interquartile range: 42–59), and the median follow-up was 12.9 months. The median rwPFS was 17.9 months (95% confidence interval: 13.3–22.5), and the median rwOS was 35.7 months (95% confidence interval: 27.8–43.6). The objective response rate was 71.4%, and the disease control rate was 95.2%. Patients receiving T-DXd in the second line experienced significantly longer rwPFS compared with those treated in later lines ( p < 0.001). Treatment-related AEs of any grade occurred in 68.4% of patients. Interstitial lung disease was reported in 21 patients (7.8%), with 4 cases being grade ⩾3.

Conclusion

In this large national real-world cohort from an LMIC, T-DXd demonstrated robust antitumor activity and a manageable safety profile in patients with HER2+ mBC. These findings are consistent with prior clinical trial data and support the applicability of T-DXd in broader clinical settings.

Schlagwörter

Stichwörter der Autor:innen

HER2+ metastatic breast cancerefficacyreal-world evidencesafetytrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Medical Oncology, Hacettepe University Faculty of Medicine, Sihhiye, Ankara 06100, Turkey.
  • Department of Medical Oncology, Koç University School of Medicine, Istanbul, Turkey.
  • Department of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
  • Department of Oncology, Faculty of Medicine, Pamukkale University, Denizli, Turkey.
  • Department of Medical Oncology, Faculty of Medicine, Çukurova University, Adana, Turkey.
  • Department of Medical Oncology, Ege University, Izmir, Turkey.

ORCID-Profile: Taha Koray Sahin, Fatih Kemik, Musa Baris Aykan, Bahadir Koylu, Nargiz Majidova, Mesut Yılmaz, Havva Yesil Cinkir, Deniz Can Guven, Sercan Aksoy

Zitieren

APA

Sahin, T. K., Kemik, F., Muglu, H., Acikgöz Yildiz, B., Biter, S., Tunbekici, S., Oruc, A., Guren, A. K., Kaban, K., Guzel, H. G., Erol, C., Aykan, M. B., Koylu, B., Ekinci, O. B., Deliktas Onur, I., Kalem, A., Altunok, O., Seyyar, M., Guney, B., …, & Aksoy, S. (2026). Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261430583

Vancouver

Sahin TK, Kemik F, Muglu H, Acikgöz Yildiz B, Biter S, Tunbekici S, et al. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261430583

BibTeX
@article{Sahin2026,
  author = {Sahin, Taha Koray and Kemik, Fatih and Muglu, Harun and Acikgöz Yildiz, Bedriye and Biter, Sedat and Tunbekici, Salih and Oruc, Ahmet and Guren, Ali Kaan and Kaban, Kerim and Guzel, Halil Goksel and Erol, Cihan and Aykan, Musa Baris and Koylu, Bahadir and Ekinci, Omer Burak and Deliktas Onur, Ilknur and Kalem, Ali and Altunok, Oguz and Seyyar, Mustafa and Guney, Bunyamin and Akdogan, Orhun and Ismayilov, Rashad and Ardic, Fadime Sinem and Yazici, Melike and Majidova, Nargiz and Turker, Sema and Esin, Ece and Cabuk, Devrim and Yasar, Hatime Arzu and Oguz, Arzu and Yazici, Ozan and Gursu, Riza Umar and Yılmaz, Mesut and Yesil Cinkir, Havva and Ates, Ozturk and Celik, Emir and Karadurmus, Nuri and Demirci, Umut and Ozturk, Banu and Mandel, Nil Molinas and Bayoglu, Ibrahim Vedat and Araz, Murat and Goker, Erdem and Bayram, Ertugrul and Erdem, Dilek and Selcukbiricik, Fatih and Basaran, Gul and Sezer, Ahmet and Dogu, Gamze Gokoz and Kemal, Yasemin and Bilici, Ahmet and Gunduz, Seyda and Guven, Deniz Can and Aksoy, Sercan},
  title = {Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261430583}
}
Kostenlos starten →